Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220642 · ClinicalTrials.gov registry record · Phase 3
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
A Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07220642: Active Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
NCT07220642 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 300 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220642, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
Primary Outcome
Measured as percentage (%).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cagrilintide
Study Locations (20)
Ontario
- Hamilton Medical Rsrch Grp - Hamilton
- Wharton Med Clin Trials - Hamilton
- Milestone Research - London
- Centricity Research Oshawa - Oshawa
- Centricity Research Toronto - Toronto
Florida
- Florida Inst For Clin Res LLC - Orlando
- Oviedo Medical Research, LLC - Oviedo
Other
- CIPREC Pueyrredon - Buenos Aires
- CEDIC Centro de Investigación Clínica - CABA
New South Wales
- Sydney Cardiometabolic Centre - Liverpool
- Hunter Diabetes Centre - Merewether
California
- Diablo Clinical Research, Inc. - Walnut Creek
Colorado
- Univ of Colorado at Denver - Aurora
Illinois
- Walgreens - Store 11760 - Oak Park
Indiana
- Midwest Inst For Clin Res - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2027-06-29 |
| Phase | Phase 3 |
What the registry record for NCT07220642 still lists
NCT07220642 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220642 names 20 study sites across 13 states, led by Ontario, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT07220642 about?
NCT07220642 is a clinical study titled "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide". This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided...
What is the current status of trial NCT07220642?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-11-05. Estimated completion is 2027-06-29.
What conditions does trial NCT07220642 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07220642?
The interventions under investigation include: Placebo (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT07220642?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220642 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220642's enrollment target sits among peer trials
300 217th of 1053 higher than 825 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI